Clinical trial • Phase III • Oncology
RILVEGOSTOMIG for Advanced hepatocellular carcinoma
Phase III trial of RILVEGOSTOMIG for Advanced hepatocellular carcinoma.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced hepatocellular carcinoma
- Trial Stage
- Phase III
- Drug Modality
- Bispecific antibody|Monoclonal antibody|Small molecule
Key dates
- Initial CTIS Submission Date
- 10-06-2025
- First CTIS Authorization Date
- 30-09-2025
Trial design
Randomised, open-label, arm c: atezolizumab + bevacizumab; dose and schedule not specified in the ctis record-controlled Phase III trial across 51 sites in Italy, Germany, Netherlands and others.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Arm C: Atezolizumab + Bevacizumab; dose and schedule not specified in the CTIS record
- Biomarker Stratified
- True, PD-L1 expression subgroups
- Target Sample Size
- 947
Eligibility
Recruits 947 adults.
Inclusion criteria
- {"criterion_text":"- Locally advanced or metastatic and/or unresectable HCC\n- WHO/ECOG performance status of 0 or 1\n- BCLC stage B (that is not eligible for locoregional therapy) or stage C. Child-Pugh Score class A\n- At least one measurable target lesion\n- Co-infected with HBV and HCV are not eligible\n- Adequate organ and bone marrow function measured during the screening period\n- Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC.\n- Disease that is not amenable to curative surgical and/or locoregional therapies. Participants who have received approved adjuvant therapy (including immune checkpoint inhibitor treatment) must have a minimum interval of 6 months between the completion of such therapy and the documented diagnosis of recurrent or metastatic disease. For participants who received locoregional therapy for HCC, locoregional therapy must have been completed ≥ 28 days prior to the baseline scan for the current study."}
Exclusion criteria
- {"criterion_text":"- Any evidence of uncontrolled intercurrent diseases\n- Bleeding or other risks. HCC related - Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.\n- Bleeding or other risks. HCC related - Central nervous system metastases or spinal cord compression (including asymptomatic and adequately treated disease)\n- Bleeding or other risks. HCC related - Prior treatment with anti-CTLA-4 and/or anti-TIGIT.\n- Bleeding or other risks. HCC related - Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment\n- Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment\n- History of another primary malignancy\n- Persistent toxicities caused by previous anti-cancer therapy excluding alopecia, not yet improved to Grade ≤ 1 or baseline\n- Clinically meaningful ascites, pleural effusion, or pericardial effusion requiring non-pharmacologic intervention to maintain symptomatic control within 6 months prior to the first scheduled dose.\n- History of active primary immunodeficiency or active infection\n- History of hepatic encephalopathy\n- Current or recent (within 10 days of first dose of study treatment) use of aspirin (≥ 325 mg/day) or treatment with dipyridamole, ticlopidine, clopidogrel, and cilostazol\n- Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purposes is ineligible"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Overall Survival (OS)","definition_or_measurement_approach":""}
Secondary endpoints
- {"endpoint_text":"- PFS, ORR, DoR by BICR per RECIST v1.1","definition_or_measurement_approach":"By BICR per RECIST v1.1"}
Recruitment
- Planned Sample Size
- 947
- Recruitment Window Months
- 50
- Consent Approach
- Informed consent is obtained from adult participants. Subject information and informed consent forms (L1 SIS and ICF) are provided; multiple language-specific ICFs and addenda are included in the documentation (examples in the record include versions in French, Spanish, Dutch, Polish, Italian and English). Specific assent processes for minors are not described in the CTIS record.
Geography
- Total Number Of Sites
- 51
- Total Number Of Participants
- 273
Italy
- Earliest CTIS Part Ii Submission Date
- 23-06-2025
- Latest Decision Or Authorization Date
- 08-04-2026
- Processing Time Days
- 289
- Number Of Sites
- 8
- Number Of Participants
- 46
Sites
- Site Name
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
- Department Name
- PROMISE
- Principal Investigator Name
- Calogero Cammà
- Principal Investigator Email
- calogero.camma@unipa.it
- Contact Person Name
- Calogero Cammà
- Contact Person Email
- calogero.camma@unipa.it
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- HepatoPancreatoBiliary Oncology Medical Oncology and Hematology Unit - Humanitas Cancer Center
- Principal Investigator Name
- Lorenza Rimassa
- Principal Investigator Email
- lorenza.rimassa@hunimed.eu
- Contact Person Name
- Lorenza Rimassa
- Contact Person Email
- lorenza.rimassa@hunimed.eu
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- UOC Internal Medicine and Gastroenterology
- Principal Investigator Name
- Antonio Gasbarrini
- Principal Investigator Email
- antonio.gasbarrini@unicatt.it
- Contact Person Name
- Antonio Gasbarrini
- Contact Person Email
- antonio.gasbarrini@unicatt.it
- Site Name
- Azienda Ospedaliero Universitaria Pisana
- Department Name
- UO Oncologia Medica 2
- Principal Investigator Name
- Gianluca Masi
- Principal Investigator Email
- gianluca.masi@unipi.it
- Contact Person Name
- Gianluca Masi
- Contact Person Email
- gianluca.masi@unipi.it
- Site Name
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
- Department Name
- Medical and Surgical Department of Digestive, Liver and Endocrine-Metabolic Diseases
- Principal Investigator Name
- Fabio Piscaglia
- Principal Investigator Email
- fabio.piscaglia@unibo.it
- Contact Person Name
- Fabio Piscaglia
- Contact Person Email
- fabio.piscaglia@unibo.it
- Site Name
- ASST Grande Ospedale Metropolitano Niguarda
- Department Name
- Medical Oncology (SC Oncologia Falck)
- Principal Investigator Name
- Katia Bruna Bencardino
- Principal Investigator Email
- katia.bencardino@ospedaleniguarda.it
- Contact Person Name
- Katia Bruna Bencardino
- Contact Person Email
- katia.bencardino@ospedaleniguarda.it
- Site Name
- Ospedale San Raffaele S.r.l.
- Department Name
- UO Oncologia Medica
- Principal Investigator Name
- Andrea Casadei Gardini
- Principal Investigator Email
- casadeigardini.andrea@hsr.it
- Contact Person Name
- Andrea Casadei Gardini
- Contact Person Email
- casadeigardini.andrea@hsr.it
- Site Name
- Azienda Ospedaliera Di Perugia
- Department Name
- Department of Medicai Oncology
- Principal Investigator Name
- Mario Mandalà
- Principal Investigator Email
- mario.mandala@unipg.it
- Contact Person Name
- Mario Mandalà
- Contact Person Email
- mario.mandala@unipg.it
Germany
- Earliest CTIS Part Ii Submission Date
- 12-09-2025
- Latest Decision Or Authorization Date
- 17-04-2026
- Processing Time Days
- 217
- Number Of Sites
- 16
- Number Of Participants
- 72
Sites
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- Klinik für Gastroenterologie, Hepatologie und Transplantationsmedizin
- Principal Investigator Name
- Leonie Jochheim
- Principal Investigator Email
- Leonie.Jochheim@uk-essen.de
- Contact Person Name
- Leonie Jochheim
- Contact Person Email
- Leonie.Jochheim@uk-essen.de
- Site Name
- Universitaetsklinikum Aachen AöR
- Department Name
- Med. Klinik III Studienzentrum Viszeralonkologie
- Principal Investigator Name
- Marie Luise Berres
- Principal Investigator Email
- mberres@ukaachen.de
- Contact Person Name
- Marie Luise Berres
- Contact Person Email
- mberres@ukaachen.de
- Site Name
- LMU Klinikum Muenchen AöR
- Department Name
- Medizinische Klinik und Poliklinik 2
- Principal Investigator Name
- Najib Ben Khaled
- Principal Investigator Email
- Najib.BenKhaled@med.uni-muenchen.de
- Contact Person Name
- Najib Ben Khaled
- Contact Person Email
- Najib.BenKhaled@med.uni-muenchen.de
- Site Name
- Technische Universitaet Dresden
- Department Name
- Medizinische Klinik I Studienzentrale Internistische Onkologie
- Principal Investigator Name
- Anke Kroecher nee Froemmel
- Principal Investigator Email
- Anke.Kroecher@ukdd.de
- Contact Person Name
- Anke Kroecher nee Froemmel
- Contact Person Email
- Anke.Kroecher@ukdd.de
- Site Name
- Universitaetsklinikum Bonn AöR
- Department Name
- Medizinische Klinik und Poliklinik 1 Onkologische Gastroenterologie
- Principal Investigator Name
- Maria Gonzalez-Carmona
- Principal Investigator Email
- maria.gonzalez-carmona@ukbonn.de
- Contact Person Name
- Maria Gonzalez-Carmona
- Contact Person Email
- maria.gonzalez-carmona@ukbonn.de
- Site Name
- Medizinische Hochschule Hannover
- Department Name
- Klinik für Gastroenterologie, Hepatologie, Infektologie, Endokrinologie
- Principal Investigator Name
- Thomas Wirth
- Principal Investigator Email
- Wirth.Thomas@mh-hannover.de
- Contact Person Name
- Thomas Wirth
- Contact Person Email
- Wirth.Thomas@mh-hannover.de
- Site Name
- Universitaetsklinikum Ulm AöR
- Department Name
- Zentrum fuer Innere Medizin Klinik für Innere Medizin I
- Principal Investigator Name
- Thomas Ettrich
- Principal Investigator Email
- thomas.ettrich@uniklinik-ulm.de
- Contact Person Name
- Thomas Ettrich
- Contact Person Email
- thomas.ettrich@uniklinik-ulm.de
- Site Name
- University Medical Center Hamburg-Eppendorf
- Department Name
- Medizinische Klinik und Poliklinik Studienambulanz Hepatologie
- Principal Investigator Name
- Johann von Felden
- Principal Investigator Email
- j.von-felden@uke.de
- Contact Person Name
- Johann von Felden
- Contact Person Email
- j.von-felden@uke.de
- Site Name
- Klinikum Dortmund gGmbH
- Department Name
- Klinik für Gastroenterologie, Hämatologie, Internistische Onkologie und Endokrinologie
- Principal Investigator Name
- Marcus-Alexander Woerns
- Principal Investigator Email
- marcus-alexander.woerns@klinikumdo.de
- Contact Person Name
- Marcus-Alexander Woerns
- Contact Person Email
- marcus-alexander.woerns@klinikumdo.de
- Site Name
- Otto Von Guericke Universitaet Magdeburg
- Department Name
- Klinik fuer Gastroenterologie, Hepatologie und Infektiologie
- Principal Investigator Name
- Marino Venerito
- Principal Investigator Email
- m.venerito@med.ovgu.de
- Contact Person Name
- Marino Venerito
- Contact Person Email
- m.venerito@med.ovgu.de
- Site Name
- Universitaetsklinikum Schleswig-Holstein AöR
- Department Name
- Medizinische Klinik I
- Principal Investigator Name
- Jens Marquardt
- Principal Investigator Email
- Jens.Marquardt@uksh.de
- Contact Person Name
- Jens Marquardt
- Contact Person Email
- Jens.Marquardt@uksh.de
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Medizinische Klinik mit Schwerpunkt Hepatologie und Gastroenterologie
- Principal Investigator Name
- Raphael Mohr
- Principal Investigator Email
- raphael.mohr@charite.de
- Contact Person Name
- Raphael Mohr
- Contact Person Email
- raphael.mohr@charite.de
- Site Name
- Stiftung Krankenhaus Bethanien Fuer Die Grafschaft Moers
- Department Name
- Klinik für Gastroenterologie und Onkologie
- Principal Investigator Name
- Mischa Franz Moeller
- Principal Investigator Email
- mischa.moeller@bethanienmoers.de
- Contact Person Name
- Mischa Franz Moeller
- Contact Person Email
- mischa.moeller@bethanienmoers.de
- Site Name
- Goethe University Frankfurt
- Department Name
- Medizinische Klinik I
- Principal Investigator Name
- Joerg Trojan
- Principal Investigator Email
- trojan@em.uni-frankfurt.de
- Contact Person Name
- Joerg Trojan
- Contact Person Email
- trojan@em.uni-frankfurt.de
- Site Name
- Universitaet Leipzig
- Department Name
- Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie und Pneumologie
- Principal Investigator Name
- Florian van Boemmel
- Principal Investigator Email
- florian.vanboemmel@medizin.uni-leipzig.de
- Contact Person Name
- Florian van Boemmel
- Contact Person Email
- florian.vanboemmel@medizin.uni-leipzig.de
- Site Name
- Krankenhaus Nordwest GmbH
- Department Name
- Institut für Klinisch-Onkologische Forschung (IKF)
- Principal Investigator Name
- Thorsten Oliver Goetze
- Principal Investigator Email
- goetze.thorsten@khnw.de
- Contact Person Name
- Thorsten Oliver Goetze
- Contact Person Email
- goetze.thorsten@khnw.de
Netherlands
- Earliest CTIS Part Ii Submission Date
- 01-09-2025
- Latest Decision Or Authorization Date
- 10-04-2026
- Processing Time Days
- 221
- Number Of Sites
- 5
- Number Of Participants
- 27
Sites
- Site Name
- Academisch Ziekenhuis Maastricht
- Department Name
- Medische Oncologie
- Principal Investigator Name
- Judith de Vos
- Principal Investigator Email
- judith.de.vos@mumc.nl
- Contact Person Name
- Judith de Vos
- Contact Person Email
- judith.de.vos@mumc.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Medische Oncologie
- Principal Investigator Name
- Daan Knapen
- Principal Investigator Email
- d.g.knapen@umcg.nl
- Contact Person Name
- Daan Knapen
- Contact Person Email
- d.g.knapen@umcg.nl
- Site Name
- Universitair Medisch Centrum Utrecht
- Department Name
- Medische Oncologie
- Principal Investigator Name
- Nadia Haj Mohammad
- Principal Investigator Email
- n.hajmohammad@umcutrecht.nl
- Contact Person Name
- Nadia Haj Mohammad
- Contact Person Email
- n.hajmohammad@umcutrecht.nl
- Site Name
- Erasmus MC
- Department Name
- Kanker Instituut
- Principal Investigator Name
- Ferry Eskens
- Principal Investigator Email
- f.eskens@erasmusmc.nl
- Contact Person Name
- Ferry Eskens
- Contact Person Email
- f.eskens@erasmusmc.nl
- Site Name
- Amsterdam UMC
- Department Name
- Medical Oncology, locatie Vumc
- Principal Investigator Name
- Johanna Wilmink
- Principal Investigator Email
- j.w.wilmink@amsterdamumc.nl
- Contact Person Name
- Johanna Wilmink
- Contact Person Email
- j.w.wilmink@amsterdamumc.nl
Poland
- Earliest CTIS Part Ii Submission Date
- 16-09-2025
- Latest Decision Or Authorization Date
- 05-05-2026
- Processing Time Days
- 231
- Number Of Sites
- 7
- Number Of Participants
- 40
Sites
- Site Name
- Szpital Kliniczny Ministerstwa Spraw Wewnetrznych I Administracji Z Warminsko-Mazurskim Centrum Onkologii W Olsztynie
- Department Name
- Klinika Onkologii i Immunologii z Oddzialem Dziennym Terapii Onkologicznej
- Principal Investigator Name
- Tomasz Lewandowski
- Principal Investigator Email
- tomasz.lewandowski@poliklinika.net
- Contact Person Name
- Tomasz Lewandowski
- Contact Person Email
- tomasz.lewandowski@poliklinika.net
- Site Name
- Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
- Department Name
- I Oddzial Onkologii Klinicznej z Chemioterapia Dzienna
- Principal Investigator Name
- Aneta Dobrzyńska-Rutkowska
- Principal Investigator Email
- adobrzynska@cozl.pl
- Contact Person Name
- Aneta Dobrzyńska-Rutkowska
- Contact Person Email
- adobrzynska@cozl.pl
- Site Name
- Uniwersyteckie Centrum Kliniczne
- Department Name
- Klinika Onkologii i Radioterapii
- Principal Investigator Name
- Ewa Szutowicz-Zielinska
- Principal Investigator Email
- ESZUT@GUMED.EDU.PL
- Contact Person Name
- Ewa Szutowicz-Zielinska
- Contact Person Email
- ESZUT@GUMED.EDU.PL
- Site Name
- Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy
- Department Name
- Ambulatorium Chemioterapii
- Principal Investigator Name
- Bogdan Zurawski
- Principal Investigator Email
- zurawskib@co.bydgoszcz.pl
- Contact Person Name
- Bogdan Zurawski
- Contact Person Email
- zurawskib@co.bydgoszcz.pl
- Site Name
- Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
- Department Name
- Klinika Onkologii i Radioterapii
- Principal Investigator Name
- Lucjan Wyrwicz
- Principal Investigator Email
- koir@nio.gov.pl
- Contact Person Name
- Lucjan Wyrwicz
- Contact Person Email
- koir@nio.gov.pl
- Site Name
- Szpital Miejski Specjalistyczny Im. Gabriela Narutowicza W Krakowie
- Department Name
- Oddzial Kliniczny Onkologii Klinicznej i Chemioterapii
- Principal Investigator Name
- Joanna Streb
- Principal Investigator Email
- dilo@narutowicz.krakow.pl
- Contact Person Name
- Joanna Streb
- Contact Person Email
- dilo@narutowicz.krakow.pl
- Site Name
- Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie
- Department Name
- Oddzial Dzienny Chemioterapii
- Principal Investigator Name
- Mariusz Kwiatkowski
- Principal Investigator Email
- sekretariat.odch@swk.med.pl
- Contact Person Name
- Mariusz Kwiatkowski
- Contact Person Email
- sekretariat.odch@swk.med.pl
France
- Earliest CTIS Part Ii Submission Date
- 22-08-2025
- Latest Decision Or Authorization Date
- 13-04-2026
- Processing Time Days
- 234
- Number Of Sites
- 8
- Number Of Participants
- 48
Sites
- Site Name
- Centre Hospitalier Universitaire De Nice
- Department Name
- Pôle de référence Hépato Gastro-Entérologie et Oncologie Digestive
- Principal Investigator Name
- Anne-Claire Frin
- Principal Investigator Email
- frin.ac@chu-nice.fr
- Contact Person Name
- Anne-Claire Frin
- Contact Person Email
- frin.ac@chu-nice.fr
- Site Name
- Centre De Lutte Contre Le Cancer Eugene Marquis
- Department Name
- Medical Oncology
- Principal Investigator Name
- Julien Edeline
- Principal Investigator Email
- j.edeline@rennes.unicancer.fr
- Contact Person Name
- Julien Edeline
- Contact Person Email
- j.edeline@rennes.unicancer.fr
- Site Name
- Centre Hospitalier Universitaire De Toulouse
- Department Name
- Service Hépatologie
- Principal Investigator Name
- Jean-Marie Péron
- Principal Investigator Email
- peron.jm@chu-toulouse.fr
- Contact Person Name
- Jean-Marie Péron
- Contact Person Email
- peron.jm@chu-toulouse.fr
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Oncology medical department
- Principal Investigator Name
- Yann Touchefeu
- Principal Investigator Email
- yann.touchefeu@chu-nantes.fr
- Contact Person Name
- Yann Touchefeu
- Contact Person Email
- yann.touchefeu@chu-nantes.fr
- Site Name
- Assistance Publique Hopitaux De Paris
- Department Name
- Liver cancer and Therapeutic Innovation Unit
- Principal Investigator Name
- Mohamed Bouattour
- Principal Investigator Email
- mohamed.bouattour@aphp.fr
- Contact Person Name
- Mohamed Bouattour
- Contact Person Email
- mohamed.bouattour@aphp.fr
- Site Name
- Centre Hospitalier Universitaire De Lille
- Department Name
- Service des Maladies de l'Appareil Digestif et de la Nutrition
- Principal Investigator Name
- Philippe Mathurin
- Principal Investigator Email
- philippe.mathurin@chu-lille.fr
- Contact Person Name
- Philippe Mathurin
- Contact Person Email
- philippe.mathurin@chu-lille.fr
- Site Name
- Hospices Civils De Lyon
- Department Name
- Oncology
- Principal Investigator Name
- Philippe Merle
- Principal Investigator Email
- philippe.merle@chu-lyon.fr
- Contact Person Name
- Philippe Merle
- Contact Person Email
- philippe.merle@chu-lyon.fr
- Site Name
- Centre Hospitalier Universitaire De Bordeaux
- Department Name
- Digestive Oncology
- Principal Investigator Name
- Jean-Frédéric Blanc
- Principal Investigator Email
- jean-frederic.blanc@chu-bordeaux.fr
- Contact Person Name
- Jean-Frédéric Blanc
- Contact Person Email
- jean-frederic.blanc@chu-bordeaux.fr
Spain
- Earliest CTIS Part Ii Submission Date
- 24-07-2025
- Latest Decision Or Authorization Date
- 14-05-2026
- Processing Time Days
- 294
- Number Of Sites
- 7
- Number Of Participants
- 40
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Digestive
- Principal Investigator Name
- María Elisa Reig
- Principal Investigator Email
- mreig1@clinic.cat
- Contact Person Name
- María Elisa Reig
- Contact Person Email
- mreig1@clinic.cat
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncology
- Principal Investigator Name
- Ángela Lamarca Lete
- Principal Investigator Email
- angela.lamarca@quironsalud.es
- Contact Person Name
- Ángela Lamarca Lete
- Contact Person Email
- angela.lamarca@quironsalud.es
- Site Name
- Hospital General Universitario Gregorio Maranon
- Department Name
- Digestive
- Principal Investigator Name
- Ana Matilla Peña
- Principal Investigator Email
- anamatillapena@gmail.com
- Contact Person Name
- Ana Matilla Peña
- Contact Person Email
- anamatillapena@gmail.com
- Site Name
- Hospital Universitario Marques De Valdecilla
- Department Name
- Oncology
- Principal Investigator Name
- Carlos López López
- Principal Investigator Email
- Carlos.lopez@scsalud.es
- Contact Person Name
- Carlos López López
- Contact Person Email
- Carlos.lopez@scsalud.es
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Digestive
- Principal Investigator Name
- Bruno Sangro
- Principal Investigator Email
- bsangro@unav.es
- Contact Person Name
- Bruno Sangro
- Contact Person Email
- bsangro@unav.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Digestive
- Principal Investigator Name
- Beatriz Mínguez Rosique
- Principal Investigator Email
- bminguez@vhebron.net
- Contact Person Name
- Beatriz Mínguez Rosique
- Contact Person Email
- bminguez@vhebron.net
- Site Name
- Hospital Universitario Marques De Valdecilla (duplicate listing in record may represent a different department)
- Department Name
- Oncology
- Principal Investigator Name
- Carlos López López
- Principal Investigator Email
- Carlos.lopez@scsalud.es
- Contact Person Name
- Carlos López López
- Contact Person Email
- Carlos.lopez@scsalud.es
Sponsor
Primary sponsor
- Full Name
- AstraZeneca AB
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- Rilvegostomig
- Active Substance
- RILVEGOSTOMIG
- Modality
- Bispecific antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Investigational Product Name
- IMJUDO (tremelimumab)
- Active Substance
- TREMELIMUMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Authorisation Status
- EU/1/22/1713/002
- Investigational Product Name
- Bevacizumab
- Active Substance
- BEVACIZUMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Investigational Product Name
- Atezolizumab
- Active Substance
- ATEZOLIZUMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Investigational Product Name
- Infliximab
- Active Substance
- INFLIXIMAB
- Modality
- Monoclonal antibody
- Routes Of Administration
- Intravenous
- Route
- Intravenous
- Investigational Product Name
- Mycophenolate mofetil
- Active Substance
- MYCOPHENOLATE MOFETIL
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- CANNABIDIOL for Advanced hepatocellular carcinoma
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer